Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 3/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 3/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | C1R | P00736 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786304 | 0.94 | PTGES (0.44) | PLATTRPA1POLBNPSR1PTGES | |
| SCHEMBL785477 | 0.79 | KDM4E (0.64) | TRPA1POLBNPSR1PTGESHDAC3 | |
| SCHEMBL801944 | 0.78 | GSK3B (0.56) | POLBNPSR1HDAC3HDAC7HDAC10 | |
| SCHEMBL801872 | 0.77 | PTGES (0.47) | TRPA1POLBNPSR1PTGESHDAC3 | |
| SCHEMBL802491 | 0.76 | PTGES (0.44) | TRPA1POLBNPSR1PTGESHDAC3 | |
| SCHEMBL957555 | 0.76 | POLB (0.55) | TRPA1POLBNPSR1PTGESHDAC3 | |
| SCHEMBL801881 | 0.75 | GSK3B (0.63) | POLBNPSR1PTGESHDAC3HDAC7 | |
| SCHEMBL801874 | 0.75 | TGFBR1 (0.45) | POLBNPSR1PTGESHDAC3HDAC7 | |
| SCHEMBL14529477 | 0.73 | POLB (0.40) | PLATPOLBNPSR1PTGESHDAC3 | |
| SCHEMBL959115 | 0.73 | POLB (0.41) | POLBNPSR1PTGESHDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872129-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-07 | — | — | US | disclosed |
| US-7491730-B2 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101037438-A | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2007-09-19 | — | — | CN | disclosed |
| CN-1319968-C | Pyrazole compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2007-06-06 | — | — | CN | disclosed |
| EP-1739087-A1 | Pyrazole compositions useful as inhibitors of gsk-3 | Vertex Pharmaceuticals Incorporated (US) | 2007-01-03 | — | — | EP | disclosed |
| EP-1532145-B1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMA (US) | 2006-09-13 | — | — | EP | disclosed |
| CN-1681815-A | Pyrazole compositions useful as inhibitors of GSK-3 | VERTEX PHARMA (US) | 2005-10-12 | — | — | CN | disclosed |
| EP-1532145-A1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | Vertex Pharmaceuticals Incorporated (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-26 | — | — | US | disclosed |
| WO-2004013140-A1 | PYRAZOLE COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118278-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3 | GSK3B, GSK3A, GSKIP | PLAT 3973/4885TRPA1 4813/4885POLB 2738/4885 |
| US-20040039007-A1 | Compositions useful as inhibitors of GSK-3 | GSK3A, GSK3B, GSKIP | PLAT 4279/4885TRPA1 4820/4885POLB 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.